XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
Xbiotech表示，第2期研究的主要终点是评估当Natrunix与ON+5FU+LV组合使用时的安全性和耐受性，在24周的治疗期间，Natrunix的任何种类的不良事件更少。
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix Arm Compared To Placebo, With Markedly Fewer Events In Specific Categories Of Adverse Events During That Time
Xbiotech表示，该2期研究的主要终点是评估Natrunix与ON+5FU+LV联合使用时的安全性和耐受性，在24周治疗期内，Natrunix组的任何类型的不良事件都比安慰剂组少，特定的不良事件类别在该期间发生的事件明显更少。
热门讨论
科技巨头财报季如火如荼，英伟达压轴会表现如何？
星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星
Moo Earnings
02/02 12:39
亚马逊盈利预告：猜测开盘价，获取奖励！